India’s Central Drugs Laboratory has rejected a batch of Bio-Med Pvt. Ltd's SURE RAB vaccine after it failed mandatory safety tests. The regulator found issues with bacterial endotoxin and bovine serum albumin levels, preventing the contaminated doses from entering the market. This incident underscores the importance of India’s strict quality control process for life-saving biological products.
India’s Central Drugs Laboratory (CDL) in Kasauli has rejected a specific batch of the human rabies vaccine produced by Ghaziabad-based Bio-Med Pvt. Ltd. The regulatory decision follows the failure of batch R011125 to meet safety standards during mandatory testing. The vaccine, known as SURE RAB, failed tests for bacterial endotoxin and bovine serum albumin. These checks are vital to ensure the product is free from harmful bacterial contaminants and that residual animal proteins are within safe limits.
Regulatory Prevention of Market Entry
The batch in question was manufactured in November 2025 and had an expiry date of October 2028. According to a communication from the CDL to the Drugs Controller General of India (DCGI) dated June 30, the batch did not comply with the required pharmacopoeial standards. Because these tests are part of a mandatory test-and-release protocol, the regulator successfully identified the issue before any doses reached patients or the public market. The rejected batch has since been discarded in accordance with official disposal guidelines.
Impact on the Rabies Vaccine Market
India faces a significant public health challenge regarding rabies, with millions of dog-bite cases reported annually. The domestic market for rabies vaccines is estimated at approximately ₹125 crore. While Bio-Med is a participant in this space, it operates alongside larger domestic players such as the Serum Institute of India, Bharat Biotech, and Indian Immunologicals.
S.P. Garg, Managing Director of Bio-Med, has stated that the quality failure is restricted to this specific batch and does not reflect the company's broader manufacturing output. The company continues to produce other batches that have cleared regulatory requirements. Industry observers note that while this rejection highlights a safety concern for the specific batch, it also demonstrates that India’s regulatory surveillance system is functioning effectively to catch quality failures before they pose a risk to patients.
Next Steps for Monitoring
For investors and public health followers, the focus remains on the company's internal quality assurance processes. Moving forward, the effectiveness of the company’s manufacturing oversight to prevent future batch failures will be a critical monitorable. Additionally, any further updates from the DCGI regarding broader facility audits or corrective actions will be the next key development to track in this situation.